Novo Nordisk Strikes $2 Billion Deal for GLP-1 Drug Licensing Rights

Novo Nordisk has announced a $2 billion licensing deal with Chinese pharmaceutical company United Laboratories International for a new weight-loss and diabetes drug. The agreement grants Novo Nordisk the rights to develop and commercialize the drug outside of China, further expanding its portfolio in the GLP-1 drug market.

As part of the deal, Novo Nordisk will pay $200 million upfront, with an additional $1.8 billion in potential milestone payments. The drug candidate, known as UBT251, is a triple agonist targeting GLP-1, GIP, and glucagon receptors. In early Phase 1 trials, patients taking the highest dose of UBT251 experienced an average weight loss of 15.1%, significantly higher than the 1.5% recorded in the placebo group.

Novo Nordisk, which developed popular weight-loss and diabetes drugs like Ozempic and Wegovy, has been a dominant player in the GLP-1 drug sector. However, the company’s stock has faced pressure in recent months. Shares of Novo Nordisk fell 3% on Monday and are down 18% year-to-date, partly due to investor concerns over a disappointing trial of a next-generation obesity drug.

Meanwhile, United Laboratories International has seen its stock surge following the announcement. Shares in the Hong Kong-listed company jumped 6% on Monday and have risen 35% this year, reflecting investor optimism about its drug development pipeline and the lucrative licensing deal with Novo Nordisk.

The agreement underscores Novo Nordisk’s continued efforts to maintain its leadership in the rapidly expanding weight-loss and diabetes treatment market. With GLP-1 drugs gaining popularity worldwide, pharmaceutical companies are increasingly investing in next-generation treatments to meet growing demand.